A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation  by Gaballa, Sameh et al.
Biol Blood Marrow Transplant 22 (2016) 141e148Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgA Two-Step Haploidentical Versus a Two-Step Matched
Related Allogeneic Myeloablative Peripheral Blood Stem
Cell TransplantationSameh Gaballa 1,*, Neil Palmisiano 1, Onder Alpdogan 1, Matthew Carabasi 1,
Joanne Filicko-O’Hara 1, Margaret Kasner 1, Walter K. Kraft 2, Benjamin Leiby 2,
Ubaldo Martinez-Outschoorn 1, William O’Hara 3, Barbara Pro 1, Shannon Rudolph 1,
Manish Sharma 1, John L. Wagner 1, Mark Weiss 1, Neal Flomenberg 1, Dolores Grosso 1
1Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
2Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania
3Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, PennsylvaniaArticle history:
Received 12 June 2015
Accepted 20 September 2015
Key Words:
Haploidentical
Matched related
Myeloablative total body
irradiation conditioning
Peripheral blood stem cell
transplantation
Two-step approachFinancial disclosure: See Acknowle
* Correspondence and reprint re
of Hematological Malignancies and
Jefferson University Hospital, 834
PA 19107.
E-mail address: samehgaballa@
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2016 American Sociea b s t r a c t
Haploidentical stem cell transplantation (SCT) offers a transplantation option to patients who lack an
HLA-matched donor. We developed a 2-step approach to myeloablative allogeneic hematopoietic stem cell
transplantation for patients with haploidentical or matched related (MR) donors. In this approach, the
lymphoid and myeloid portions of the graft are administered in 2 separate steps to allow ﬁxed T cell dosing.
Cyclophosphamide is used for T cell tolerization. Given a uniform conditioning regimen, graft T cell dose, and
graft-versus-host disease (GVHD) prophylaxis strategy, we compared immune reconstitution and clinical
outcomes in patients undergoing 2-step haploidentical versus 2-step MR SCT. We retrospectively compared
data on patients undergoing a 2-step haploidentical (n ¼ 50) or MR (n ¼ 27) peripheral blood SCT for high-
risk hematological malignancies and aplastic anemia. Both groups received myeloablative total body irradi-
ation conditioning. Immune reconstitution data included ﬂow cytometric assessment of T cell subsets at day
28 and 90 after SCT. Both groups showed comparable early immune recovery in all assessed T cell subsets
except for the median CD3/CD8 cell count, which was higher in the MR group at day 28 compared with that in
the haploidentical group. The 3-year probability of overall survival was 70% in the haploidentical group and
71% in the MR group (P ¼ .81), while the 3-year progression-free survival was 68% in the haploidentical group
and 70% in the MR group (P ¼ .97). The 3-year cumulative incidence of nonrelapse mortality was 10% in the
haploidentical group and 4% in the MR group (P ¼ .34). The 3-year cumulative incidence of relapse was 21% in
the haploidentical group and 27% in the MR group (P ¼ .93). The 100-day cumulative incidence of overall
grades II to IV acute GVHD was higher in the haploidentical group compared with that in the MR group (40%
versus 8%, P < .001), whereas the grades III and IV acute GVHD was not statistically different between both
groups (haploidentical, 6%; MR, 4%; P ¼ .49). The cumulative incidence of cytomegalovirus reactivation was
also higher in the haploidentical group compared to the MR group (haploidentical, 68%; MR, 19%; P < .001).
There were no deaths from GVHD in either group. Using an identical conditioning regimen, graft T cell dose,
and GVHD prophylaxis strategy, comparable early immune recovery and clinical outcomes were observed in
the 2-step haploidentical and MR SCT recipients.
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Allogeneic stem cell transplantation (SCT) offers a
potentially curative therapy for patients with hematological
disorders, but it is limited by the lack of available, matched
HLA-related donors for many patients. Matched unrelated,
haploidentical, and cord blood donors have been used as
alternatives with varying levels of success. Haploidentical
S. Gaballa et al. / Biol Blood Marrow Transplant 22 (2016) 141e148142SCT (haploSCT) has the advantage of rapid availability, rela-
tively lower cost, and widespread access utilizing siblings,
parents, or offspring [1].
Historically, haploSCTwas associated with poor outcomes
with high rates of high-grade acute graft-versus-host disease
(GVHD) [2-4]. HaploSCT became a viable treatment option
when T celledepletion techniques were developed to
decrease the incidence of severe GVHD [5-7] and antithy-
mocyte globulin was added to increase engraftment rates
[8,9]. However, the lymphodepletion associated with these
methods resulted in delayed immune recovery and, conse-
quently, a high incidence of post-SCT infectious complica-
tions and nonrelapse mortality (NRM) [10-12].
In recent years, haploSCT approaches that attenuate
rather than deplete T cells from donor grafts have resulted
in less infectious mortality and improved patient outcomes
[13-17]. The use of post-SCT cyclophosphamide, which
preferentially depletes alloreactive T cells, has been revolu-
tionary in decreasing the incidence of mortality from GVHD
and infection after haploSCT [18]. Subsequently, some
studies have shown comparable outcomes after haploSCT
with cyclophosphamide tolerization when compared with
matched related (MR) and matched unrelated SCT [19-21].
Although the intent of these studies was to highlight the
safety of haploSCT using cyclophosphamide as GVHD pro-
phylaxis, they are characterized by the use of heterogeneous
stem cell sources and, by extension, T cell doses, conditioning
intensities, and GVHD prophylaxis among the comparison
groups. As a result, it is difﬁcult to draw ﬁrm conclusions
about the quality of outcomes between 1 donor source
versus another.
Several studies have reported relapse rates in excess of
50% in post-SCT cyclophosphamide trials, possibly due to
the use of nonmyeloablative conditioning, the lower dose
of T cells associated with a marrow graft, or a combination of
both [18,22]. These ﬁndings have stimulated the use of
myeloablative conditioning and/or peripheral blood stem
cells grafts to decrease relapse rates. Relapse rates are less
than 40% in some trials after haploidentical SCT using pe-
ripheral blood stem cells as a graft source, which contain
higher T cell doses than marrow grafts [23,24]. These results
suggest that there is a range of T cell doses that is important
for graft-versus-tumor (GVT) effects in haploSCT [24-26].
Standardization of T cell doses would allow more effective
comparisons of haploSCT regimens and strengthen the abil-
ity to compare GVT effects among the various donor sources.
To address these issues, we developed a “2-step” mye-
loablative peripheral blood approach to SCT in which the
lymphoid and myeloid portions of the graft are administered
separately [27]. In this approach, a ﬁxed T cell infusion con-
taining 2  108 cells/kg CD3þ cells (SCT step 1) is adminis-
tered, followed 2 days later by cyclophosphamide to
eradicate alloreactive donor and surviving recipient T cells.
A CD34-selected product (containing <5  104/kg T cells) is
then administered 24 hours after the completion of cyclo-
phosphamide (SCT step 2).
This approach has 2 unique features. First, it allows
separate control over the infused T cell dose and CD34 stem
cell dose. This could allow future studies to titrate the infused
T cell dose or CD34 stem cell dose. Second, it spares the stem
cell product from exposure to cyclophosphamide, whichmay
help accelerate count recovery. Although high-dose cyclo-
phosphamide is not toxic to stem cells because of high levels
of expression of aldehyde dehydrogenase enzyme [28], it is
unknown if this holds true for the more committedprogenitor cells that could potentially get damaged by
cyclophosphamide and lead to slower engraftment.
In 2008, we initiated a 2-step trial using MR donors
with identical T cell dosing, conditioning regimen, and GVHD
prophylaxis strategy as our haploidentical study. This
trial investigated whether this type of approach could lower
GVHD incidence and severity in recipients ofMR grafts. Given
the identical conditioning regimen, graft T cell dose, and
GVHD prophylaxis regimens used in both the haploSCT and
MR trials, we retrospectively compared the immune recovery
and clinical outcomes in both groups in this current study.
We hypothesized that immune recovery would be similar in
both groups when an identical transplantation approach is
used, including an identical T cell dose, and that this could, in
turn, translate into similar survival rates. If NRM rates were
equivalent, this would facilitate future prospective trials
examining differences in GVT effects between both groups.
METHODS
Design
The Thomas Jefferson University institutional review board approved
both the 2-step haploidentical SCT and the 2-step MR research protocols.
All patients signed an informed consent as a part of their enrollment on the
2-step clinical trials in accordance with the Declaration of Helsinki. In this
retrospective study, all adult patients who underwent a myeloablative
peripheral blood haploSCT or MR SCT using the 2-step approach (n¼ 87) for
high-risk hematological malignancies or aplastic anemia were considered
for inclusion. Patients were excluded if they had active leukemia at the time
of transplantation (9 patients in the haploSCT group and 1 in the MR group)
because the small numbers did not allow meaningful comparisons among
these high-risk patients. The remaining 77 patients (50 in the haploSCT
group and 27 in the MR SCT group) were included in this study. All patients
were treated at Thomas Jefferson University Hospital between March 2007
and December 2014.
Transplantation Protocol and the 2-Step Approach
Themyeloablative conditioning regimen consisted of 12 Gy of total body
irradiation administered in 8 fractions over 4 days. A large ﬁxed T cell dose
(2  108 cells/kg) was administered after the last fraction of total body
irradiation (SCT step 1), followed 2 days later by cyclophosphamide 60 mg/
kg/day for 2 days (Figure 1). A CD34-selected donor stem cell product was
infused 24 hours after the completion of cyclophosphamide on day 0 (SCT
step 2). Before 2010, CD34 selection was accomplished using the Isolex 300i
magnetic cell selection system (Baxter, Deerﬁeld, IL). Starting in 2010, the
CliniMacs CD 34 Reagent System (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) was used for this purpose under Investigational Device Exemptions
(IDEs) 14336 and 15721. Tacrolimus and mycophenolate mofetil were initi-
ated on day 1 for GVHD prophylaxis. All patients received growth factor
support (granulocyte macrophage colonyestimulating factor 250 mg/m2)
starting on day þ1. In the absence of GVHD, mycophenolate mofetil was
discontinued on day 28 and, in the absence of GVHD, a tacrolimus taper was
initiated on day þ60 after SCT.
Endpoints
The primary objective was comparative assessment of early immune
recovery in recipients of haploSCT versus that after MR SCT. The primary
endpoint was immune recovery as measured by quantitative measurement
of the CD3/CD4, CD3/CD8, NKbright, and NKdim cell counts on days 28 and 90
after SCT using ﬂow cytometry. The immune recovery panel values were
used when done within 1 week from day 28 or 2 weeks from day 90. The
secondary endpoint was to compare clinical outcomes between both groups
including acute GVHD, chronic GVHD, relapse rate, NRM, relapse-related
mortality (RRM), and overall survival (OS). Patients who relapsed or had
mixed chimerism on day 28 or 90 were removed from the immune recon-
stitution analysis but were included in the outcomes analysis.
Deﬁnitions
Acute GVHD was assessed using the Glucksberg grading criteria [29].
Chronic GVHD was assessed using the National Institutes of Health
consensus criteria for GVHD [30]. White cell engraftment was deﬁned as an
absolute neutrophil count of more than 0.5 109/L for at least 3 consecutive
days after transplantation. Platelet engraftment was deﬁned as a platelet
count more than 20,000/mL without a platelet transfusion for the 7 pre-
ceding days.
Table 1
Patient Characteristics
Characteristic Haploidentical
SCT (%) n ¼ 50
Matched
Related SCT
(%) n ¼ 27
P Value
Recipient age, median
(range), yr
49 (21-65) 49 (25-63) .74*
Recipient sex (M/F) 28/22 18/9 .47y
Donor age, median
(range), yr
36 (18-65) 47 (27-68) .06*
CMV status at time of transplantation (recipient/donor)
Recipientþ/donor (%) 13 (26) 6 (22) .72z
Recipientþ/donorþ (%) 16 (32) 7 (25)
Recipient/donorþ (%) 5 (10) 5 (18)
Recipient/donor (%) 16 (32) 9 (33)
Donor type
Sibling 15 (30) 26 (96%) <.001z
Parent 12 (24) 1 (4)
Child 23 (46) 0
HCT-CI
0-2 (%) 27 (54) 17 (63) .46y
3 (%) 23 (46) 9 (33)
Missing 0 1 (4)
Disease
AML (%) 27 (54) 11 (41) .31z
CR1 23 11
CR2 or greater 4 0
MDS or MPD 3 (6) 4 (15) .43y
ALL 14 (28) 6 (22) .35y
CR1 8 5
CR2 or greater 6 1
NHL 5 (10) 6 (22) .61y
CR 2 3
PR 3 3
Aplastic anemia 1 0 NA
Disease risk indexx
Very high 1 (2) 2 (7) .20z
High 14 (28) 3 (11)
Intermediate 32 (64) 22 (82)
Low 2 (4) 0
Not applicable 1 (2) 0
M indicates male; F, female; HCT-CI, hematopoietic cell trans-
plantationespeciﬁc comorbidity index; AML, acute myeloid leukemia; CR,
complete remission; MDS, myelodysplastic syndrome; MPD, myeloprolif-
erative disease; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin’s
lymphoma; PR, partial remission; NA, not applicable.
Bold typeface indicates statistical signiﬁcance.
* Mann Whitney Test.
y Fisher’s exact test.
z Chi-Square Test.
x Disease risk index by Armand et al. [32].
Figure 1. Outline of the 2-step approach. After total body irradiation conditioning, patients receive a donor lymphocyte infusion product containing 2  108 CD3þ
cells/kg. This is followed by 2 days of rest and then 2 doses of high-dose cyclophosphamide. A CD34-selected stem cell product is then infused.
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Groups were compared with respect to baseline clinical and de-
mographic characteristics using Pearson’s chi-square test or Fisher’s exact
test. Cell counts of CD3/CD4, CD3/CD8, CD56bright, and CD56dim were
compared between the HaploSCT and MR groups using the Mann-Whitney
test. OS was deﬁned as the time from day 0 after transplantation to death
from any cause. OS was estimated using the Kaplan-Meier method, and the
log-rank test was used to test for differences in survival between the hap-
loSCT and MR groups. Cumulative incidences of relapse, acute GVHD grades
II to IV, and acute GVHD grades III and IV were calculated using death as a
competing risk. Competing risk analysis was performed using the freely
available EZR software version 1.24 using the Gray test [31]. All other ana-
lyses were performed using SPSS version 21.
RESULTS
Patient Population
The patient characteristics and indications for SCT are
summarized in Table 1. The median follow-up was 3 years
and 2months (range,13 to 95months) in the haploSCTgroup
and 4 years (range, 1 to 76 months) in the MR group. Donors
for the haploSCT patients tended to be younger compared
to those for the MR group (median age, 36 years versus
47 years). Both groups received an identical T cell dose
(2  108/kg) in step 1 of the SCT. The CD34 cell dose in step 2
of the SCT was similar (median dose, 4.45 versus 4.9 106/kg
in the haploSCT and MR groups, respectively, P ¼ .80). The T
cell content in the CD34-selected product (step 2) was
minimal in both groups (median content, 3.35  103/kg and
3.59  103/kg in the haploSCT and MR groups, respectively).
Immune Recovery in the HaploSCT and MR Setting
The CD3/CD8 cells were higher in the MR group at day
28 compared to the haploSCT group (median 98 versus
39 cells/uL, P ¼ .029). Otherwise, the immune recovery
among all other T cell subsets including CD4þ, NKbright, and
NKdim cells at days 28 and 90 was similar between the
haploSCT and MR groups (Figure 2).
Transplantation Outcomes
Engraftment
Successful engraftment was seen in 96% and 100% of
haploSCT and MR SCT patients, respectively. The median
time to ANC recovery was 11 days in both groups and the
median platelet recovery was 17 and 18 days in the haploSCT
and MR groups, respectively.
Haploidentical immunological storm
During the 2 days of rest after the donor lymphocyte
infusion, a “haploidentical immunological storm,” charac-
terized by high fever (median, 103.5F; range, 99.4F to
105.5F), diarrhea, and skin rash, was observed in the hap-
loSCT group and consistently resolved with the administra-
tion of cyclophosphamide. With the exception of 1 patient inthe haploSCT group, all others developed a fever >100.4F.
The fever only lasted for 2 days, during which time the
patients were managed conservatively with particular
attention to ﬂuid balance and no steroids were used. This
syndrome was not observed in the MR group, although some
patients in this cohort experienced low-grade fevers
(median, 99.6F) during this time.
Figure 2. Immune reconstitution. Immune reconstitution at day 28 (A) and at day 90 (B) after transplantation.
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The 100-day cumulative incidence of overall grades II to
IV acute GVHD was higher in the haploSCT compared to theMR group (40% versus 8%, P < .001) (Table 2, Figure 3A).
Thirty-three percent of the acute GVHD in the haploSCT
group was due to single-organ grade II skin GVHD. Skin
Table 2
Transplantation Outcomes
Outcome Haploidentical
SCT
Matched
Related
SCT
P Value
100-day CI of CMV reactivation 67% 19% <.001*
CI of grade II-IV aGVHD
100-day 40% 8% .002*
2-year 48% 12%
CI of grade III-IV aGVHD
100 Day 6% 4% .49*
2-year 8% 4%
2-year CI of cGVHD 19% 12% .47*
2-year CI of severe cGVHDy 4% 8% .49*
3-year CI of relapsed disease 22% 27% .58*
CI NRM
100-day NRM 6% 4% .38y
3-year NRM 10% 4%
CI RRM
3-year RRM 21% 25% .69*
Causes of deaths
Relapsed disease 10 (20) 6 (22) d
Non-RRM 5 (10) 1 (4) d
Toxicity 3 (6) 1 (4) d
Infection 2 (4) 0 d
GVHD 0 0 d
CI indicates cumulative incidence; aGVHD, acute graft-versus-host disease;
cGVHD, chronic graft-versus-host disease.
* Gray Test.
y cGVHD severity by National Institutes of Health consensus criteria.
Figure 3. Cumulative incidence of GVHD. Acute GVHD (aGVHD) grades II to IV (A), a
S. Gaballa et al. / Biol Blood Marrow Transplant 22 (2016) 141e148 145GVHD quickly responded to steroids or steroids plus photo-
pheresis in all patients.
The 100-day cumulative incidence of grades III and IV
acute GVHDwas similar in both the haploSCT and MR groups
(6% versus 4%, P¼ .49) (Table 2, Figure 3B). Therewas a single
patient in the haploSCT group with grade 4 acute GVHD with
skin and liver involvement that responded completely to
steroids. None of the patients in the MR group experienced
grade IV acute GVHD. There were no deaths in either group
from acute GVHD.
The cumulative incidence of chronic GVHD at 2 years was
not statistically different between the haploSCT and the MR
groups (19% in the haploSCT group versus 12% in the MR
group, P ¼ .47); nor was the 2-year incidence of severe
chronic GVHD (4% in the haploSCT group versus 8% in the MR
group, P ¼ .49) (Table 2; Figure 3C,D).
OS and disease control
The 3-year OS was 70% in the haploSCT group versus
71% in the MR group (P ¼ .81) and the 3-year progression-
free survival was 68% versus 70%, respectively (P ¼ .97)
(Figure 4A,B). The primary cause of death in both groups was
relapsed disease with a 3-year cumulative incidence of RRM
of 21% in the haploSCT group versus 25% in the MR group
(P¼ .69). The 3-year cumulative incidence of NRMwas low in
both groups (10% in the haploSCT group versus 4% in the MRGVHD grades III and IV (B), chronic GVHD (C), and severe chronic GVHD (D).
Figure 4. Overall survival (A) and progression-free survival (B).
S. Gaballa et al. / Biol Blood Marrow Transplant 22 (2016) 141e148146group, P ¼ .34) (Figure 5B). There were no deaths from GVHD
(Table 2). The 3-year cumulative incidence of relapse was
comparable in both groups (27% in the MR group versus 21%
in the haploSCT group, P ¼ .93) (Figure 5A).
CMV reactivation
Cytomegalovirus (CMV) reactivation was determined
using PCR measurement of the viral load. Based on sero-
positivity of the recipient, donor, or both, 34 patients in the
haploSCT and 18 patients in the MR groups were at risk for
CMV reactivation. CMV reactivation among these patientsFigure 5. Cumulative incidence of relapse (A)was higher in the haploSCT group compared with those in
the MR group (cumulative incidence 67% versus 19%,
P < .001). The median time to develop CMV viremia was
26 days in the haploSCT group and 36 days in the MR group.
There were no new primary CMV infections in CMV-
seronegative patients undergoing SCT from CMV-negative
donors in both groups. Among haploSCT recipients, CMV
reactivation was similar among patients with evidence
of acute GVHD (cumulative incidence, 68%) and without
evidence of aGVHD (cumulative incidence, 65%) (P ¼ .78).
Pre-emptive anti-CMV therapy was initiated in both groupsand cumulative incidence of NRM (B).
S. Gaballa et al. / Biol Blood Marrow Transplant 22 (2016) 141e148 147when CMV PCR was detected on routine surveillance, and no
CMV tissue disease was encountered using this strategy.
DISCUSSION
The aim of this study was to compare early immunolog-
ical recovery and clinical outcomes after haploSCT versus
those after MR SCT. Strengthening this analysis was the
homogeneity of the treatment in the 2 groups. To our
knowledge, this is the ﬁrst analysis to compare early immune
recovery and clinical outcomes between haploSCT versus MR
SCT using similar doses of peripheral blood mobilized
CD34 cells and identical conditioning regimens, identical
GVHD prophylaxis, and utilizing the unique 2-step approach
with identical T cell doses. Based on this uniformity, we
hypothesized that immune recovery and other clinical
outcomes would be similar after haploSCT versus MR SCT.
Although we noted some key differences in immune recon-
stitution and GVHD incidence, our analysis supports this
hypothesis.
There were no signiﬁcant differences in quantitative
recovery measures among most immune cell subsets by day
28 and day 90. This early immune recovery was associated
with a similarly low infectious mortality in both groups,
suggesting a meaningful qualitative immune recovery as
well. Higher CD3/CD8 counts at day 28 were observed in the
MR group than in the haploSCT group. This difference may be
due to a greater proportion of CD3/CD8 cells being activated
after the donor lymphocyte infusion and eligible for elimi-
nation by cyclophosphamide in the more HLA-disparate
haploSCT recipient-donor pairs. Nevertheless, this ﬁnding
did not result in differences in infectious mortality between
the groups. Our results agree with those from a recent study
by Di Stasi et al., demonstrating similar immunological re-
covery among bone marrow haploSCT compared to matched
unrelated or MR donor sources [21]. Differences were also
noted in the rate of CMV reactivation between the 2 groups.
Although no patient in either cohort developed CMV tissue
disease or died from CMV infection, CMV reactivation was
signiﬁcantly more prevalent in the haploSCT group. This
ﬁnding agrees with those from other studies reporting a
higher incidence of CMV reactivation in patients receiving a
haploSCT [33,34].
In our study, the higher frequency of CMV reactivation in
the haploidentical compared with that in the MR group was
not related to an increased number of CMV-positive donors
or recipients or to the occurrence of GVHD. Similarly, it does
not appear to be related to the pace of lymphocyte recovery
or the absolute number of lymphocyte subsets in these
2 groups. It is possible that during the immuno-storm, which
occurs in the haploidentical but not MR patients, more
signiﬁcant depletion of recipient antigen-presenting cells
(APCs) renders the haploidentical recipients more vulnerable
until APC populations are repopulated. Alternatively, it is
possible that HLA disparity reduces the efﬁciency of T cell
interactions with host APCs or tissues early on after trans-
plantation. Although both groups achieve control of CMV
with time and with removal of immune suppression, eluci-
dation of the pathogenic mechanisms underlying this higher
frequency is warranted because CMV reactivation remains a
signiﬁcant cause of morbidity.
Our secondary objective was to compare clinical out-
comes between the 2 groups. Engraftment was prompt in
all patients with the use of a myeloablative conditioning
regimen and the high donor T cell dose. The less than 100%
engraftment rate for the haploSCT group was based onrejection in the presence of donor-speciﬁc HLA antibodies in
2 patients treated on the initial study in 2009. Since that
time, patients undergoing haploSCT are rigorously screened
for donor-speciﬁc HLA antibodies, resulting in nearly uni-
versal engraftment despite the mismatched graft.
With comparable engraftment and early immunological
recovery in both groups, we evaluated next whether this
would translate into similar rates of survival in both groups.
There was a higher incidence of grades II to IV acute GVHD in
the haploSCT group (40%) than in the MR group (8%). This
higher incidence of acute GVHD did not affect survival or
NRM rates given that there were no deaths from acute GVHD
in either group. This seemingly paradoxical ﬁnding is
accounted for by the fact that the majority of the acute GVHD
in the HaploSCT group was grade II single-organ skin
involvement, which was easily controlled in all patients with
steroids or steroids plus photopheresis. In fact, the incidence
of grades III and IV acute and chronic GVHD were not
signiﬁcantly different between both groups (8% versus 4%
and 21% versus 14%, respectively). In addition, the overall
incidence of grades II to IV acute GVHD in the MR group in
this cohort was extremely low compared with what would
be expected in an HLA MR or matched unrelated donor
(MUD) SCT using conventional GVHD prophylaxis. These
rates have historically ranged from 30% to 40% in MR SCT
and up to 60% in MUD SCT, according to a recent Center for
International Blood and Marrow Transplant Research anal-
ysis [35,36].
We found no differences in the 3-year OS or progression-
free survival in patients undergoing haploSCT versus MR SCT
because of similar 3-year NRM and RRM in both groups. Both
groups received myeloablative conditioning, yet the 3-year
NRM was very low in both groups (10% and 4% in the
HaploSCTandMR group, respectively), possibly because both
groups of patients were relatively young (49 years in both
groups). We did not observe a difference in the incidence of
relapse between the 2 groups in the setting of a uniform
conditioning regimen and identical graft T cell dose. The
major cause of death in all patients was relapsed disease
rather than nonrelapse complications. These ﬁndings
contrast sharply to earlier experiences with T celledepleted
haploSCT, where NRM was a major obstacle to long-term
survival because of delayed immune recovery and high in-
fectious mortality [10-12].
Our ﬁndings are in agreement to those from 2 recent
articles by Bashey et al. and Di Stasi et al. who noted similar
OS rates when comparing bone marrow haploSCT using
post-transplantation cyclophosphamide to either MR or
MUD SCT using conventional GVHD prophylaxis [19,21].
Unlike the ﬁndings in our analysis, they reported a similar
overall grades II to IV acute GVHD rate and an even lower
chronic GVHD rate in the haploSCT compared with either
MR or MUD SCT [18]. As previously noted, these differences
may be because the MR and MUD groups in these studies
received conventional GVHD prophylaxis and not post-
transplantation cyclophosphamide.
The limitations of our analysis include its retrospective
nature, in which there were potentially undetected in-
ﬂuences on study outcomes and confounders of differences
between groups, and the small number of subjects, especially
in the MR SCT group, which decreased the power to detect
differences between both groups. The analysis took place at a
single institution, which increased consistency in the treat-
ment of the comparison groups but limited the number of
subjects available for analysis.
S. Gaballa et al. / Biol Blood Marrow Transplant 22 (2016) 141e148148In conclusion, we found comparable early immune
recovery and clinical outcomes in patients receiving pe-
ripheral blood haploSCT and after MR SCT using an identical
SCT approach. The ﬁndings at our institution and others
suggest that the use of a haploidentical donor is a safe
alternative donor option. Although RRM and NRM were not
signiﬁcantly different between the 2 groups, SCT-related
morbidity was observed in the haploSCT group in the form
of a greater rate of CMV reactivation and a higher incidence
of grade II acute GVHD. The comparable outcomes suggest
that haploSCT should be considered for the same clinical
indications and disease states as MR SCT. Finally, a prospec-
tive randomized multicenter trial comparing haploSCT and
MUD SCT including both clinical and cost of care endpoints
now appears warranted to assess where and when these
options should be utilized for patients requiring SCT but
lacking a matched sibling donor.
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